Waystar Reports Strong Q4 & FY25 Results, Provides Positive 2026 Revenue and Profit Guidance
summarizeSummary
Waystar Holding Corp. announced strong fourth quarter and full-year 2025 financial results, with significant revenue growth and healthy profitability, alongside positive guidance for fiscal year 2026.
check_boxKey Events
-
Strong Q4 2025 Performance
Reported Q4 2025 revenue of $303.5 million, a 24% increase year-over-year, with net income of $20.0 million and adjusted EBITDA margin of 43%.
-
Solid Full Year 2025 Results
Achieved full fiscal year 2025 revenue of $1,099.3 million, up 17% year-over-year, with net income of $112.1 million and adjusted EBITDA margin of 42%.
-
Positive 2026 Guidance
Provided fiscal year 2026 guidance expecting total revenue between $1.274 billion and $1.294 billion, and non-GAAP net income per share between $1.59 and $1.68.
-
Growth Drivers Highlighted
CEO Matt Hawkins noted record bookings, successful integration of the Iodine acquisition, and accelerating AI-powered innovation as key contributors to growth.
auto_awesomeAnalysis
Waystar Holding Corp. delivered robust financial performance for both the fourth quarter and full fiscal year 2025, exceeding $1 billion in annual revenue. The company's Q4 revenue grew 24% year-over-year, driven by strong subscription and volume-based revenue. Management highlighted record bookings, successful integration of the Iodine acquisition, and accelerated AI-powered innovation as key drivers. The positive 2026 guidance, projecting continued double-digit revenue growth and increased profitability, suggests a confident outlook for the company's healthcare payment software platform. This strong performance and optimistic forecast are particularly notable as the stock is currently trading near its 52-week low, potentially indicating a favorable entry point for investors if the company continues to execute on its growth strategy.
At the time of this filing, WAY was trading at $22.41 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $21.45 to $48.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.